Complex regional pain syndrome type 1 (CRPS1) is a form of complex regional pain syndrome in which the pain is disproportionate to any known inciting event and is characterized by continuous pain, all...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on CRPS1 is limited due to its complex nature and the fact that it affects a relatively small population. This rarity makes systematic clinical studies challenging. Furthermore, the variability in symptoms and responses to treatment complicates the characterization of the condition, leading to gaps in our understanding.
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
There are currently 13 orphan drugs designated for CRPS1, including afatinib, baclofen, delta-9-tetrahydrocannabinol and cannabidiol, hydromorphone, and ketamine. While these treatments are in various stages of development, none have been approved yet. Additionally, there are active clinical trials that may offer opportunities for participation. For more details, you can explore ongoing trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=complex%20regional%20pain%20syndrome%20type%201.
Actionable guidance for navigating care for complex regional pain syndrome type 1
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the complex regional pain syndrome type 1 community
Helpful links for rare disease information and support
The documentation on CRPS1 is limited due to its complex nature and the fact that it affects a relatively small population. This rarity makes systematic clinical studies challenging. Furthermore, the variability in symptoms and responses to treatment complicates the characterization of the condition, leading to gaps in our understanding.
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
There are currently 13 orphan drugs designated for CRPS1, including afatinib, baclofen, delta-9-tetrahydrocannabinol and cannabidiol, hydromorphone, and ketamine. While these treatments are in various stages of development, none have been approved yet. Additionally, there are active clinical trials that may offer opportunities for participation. For more details, you can explore ongoing trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=complex%20regional%20pain%20syndrome%20type%201.
Actionable guidance for navigating care for complex regional pain syndrome type 1
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the complex regional pain syndrome type 1 community
Helpful links for rare disease information and support
The documentation on CRPS1 is limited due to its complex nature and the fact that it affects a relatively small population. This rarity makes systematic clinical studies challenging. Furthermore, the variability in symptoms and responses to treatment complicates the characterization of the condition, leading to gaps in our understanding.
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
There are currently 13 orphan drugs designated for CRPS1, including afatinib, baclofen, delta-9-tetrahydrocannabinol and cannabidiol, hydromorphone, and ketamine. While these treatments are in various stages of development, none have been approved yet. Additionally, there are active clinical trials that may offer opportunities for participation. For more details, you can explore ongoing trials at ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=complex%20regional%20pain%20syndrome%20type%201.
Actionable guidance for navigating care for complex regional pain syndrome type 1
To navigate CRPS1, consider consulting a pain management specialist who has experience with complex regional pain syndromes. Additionally, you can connect with the Reflex Sympathetic Dystrophy Syndrome Association (RSDSA) at https://rsds.org for support and resources. Participating in patient registries or natural history studies can also contribute to a better understanding of the condition and may provide access to new treatments. While genetic counseling is not currently indicated due to the absence of identified genetic factors, it may be beneficial for family planning discussions.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the complex regional pain syndrome type 1 community
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 8, 2026
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
2 peer-reviewed sources from PubMed
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.